Therapeutic Potential of Cannabinoids in Psychosis

  title={Therapeutic Potential of Cannabinoids in Psychosis},
  author={F. Markus Leweke and Juliane K. Mueller and Bettina N Lange and Cathrin Rohleder},
  journal={Biological Psychiatry},

Figures and Tables from this paper

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
Cannabidiol is a promising candidate as an effective and mechanistically different antipsychotic treatment with a favourable side-effect profile and the level of proof of safety and efficacy required to approve the therapeutic use of cannabidio in schizophrenia is currently lacking.
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
After some individual treatment attempts, the first randomized, double-blind controlled clinical trial demonstrated that in acute schizophrenia cannabidiol exerts antipsychotics properties comparable to the antipsychotic drug amisulpride while being accompanied by a superior, placebo-like side effect profile.
Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice
Test in mice the potential therapeutic use of pregnenolone against acute psychotic-like effects of Δ9-tetrahydrocannabinol, the main psychoactive component of cannabis found that it blocks a wide spectrum of THC-induced endophenotypes typically associated with psychotic- like states, including impairments in cognitive functions, somatosensory gating and social interaction.
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness.
Investigating the Role of the Endocannabinoid System in Early Psychosis
Some of the evidence supporting the role of eCB system in psychosis is summarized, as well as the current understanding of the neurocognitive underpinnings of psychosis, to propose a pharmacological cannabinoid challenge paradigm to examine how experimental perturbation of the e CB system may be related to abnormalities in the brain networks implicated in psychosis.
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways
The mechanism of action at the endocannabinoid system is described, mainly in the brain, and effects of cannabinoid ligands on other neurotransmitter systems will also be described, such as dopamine, serotonin, glutamate, noradrenaline, opioid, and GABA.
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Preclinical and clinical reports regarding the effects of CBD on the regulation of the reinforcing, motivational and withdrawal-related effects of different drugs of abuse such as alcohol, opioids (morphine, heroin), cannabinoids, nicotine, and psychostimulants are reviewed.
New drugs in psychiatry: focus on new pharmacological targets
Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression.
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia, and preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings.


Cannabinoids and schizophrenia
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Molecular characterization of a peripheral receptor for cannabinoids
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids.
Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
Pharmacological and molecular targets in the search for novel antipsychotics
The recent enthusiasm among clinicians for the so‐called "atypical antipsychotics" has both improved treatment for schizophrenic patients and provided a welcome stimulus for basic research on
Cannabidiol monotherapy for treatment-resistant schizophrenia
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state, and the endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects.
Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System
Modulation of anxiety through blockade of anandamide hydrolysis
The results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
  • P. Roser, F. Vollenweider, W. Kawohl
  • Psychology, Biology
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2010
Preclinical and clinical studies investigating the potential antipsychotic effects of both CBD and SR141716 are presented together with the possible underlying mechanisms of action.